Literature DB >> 18199761

Glial dysfunction in parkin null mice: effects of aging.

Rosa M Solano1, Maria J Casarejos, Jamie Menéndez-Cuervo, Jose A Rodriguez-Navarro, Justo García de Yébenes, Maria A Mena.   

Abstract

Parkin mutations in humans produce parkinsonism whose pathogenesis is related to impaired protein degradation, increased free radicals, and abnormal neurotransmitter release. The role of glia in parkin deficiency is little known. We cultured midbrain glia from wild-type (WT) and parkin knock-out (PK-KO) mice. After 18-20 d in vitro, PK-KO glial cultures had less astrocytes, more microglia, reduced proliferation, and increased proapoptotic protein expression. PK-KO glia had greater levels of intracellular glutathione (GSH), increased mRNA expression of the GSH-synthesizing enzyme gamma-glutamylcysteine synthetase, and greater glutathione S-transferase and lower glutathione peroxidase activities than WT. The reverse happened in glia cultured in serum-free defined medium (EF12) or in old cultures. PK-KO glia was more susceptible than WT to transference to EF12 or neurotoxins (1-methyl-4-phenylpyridinium, blockers of GSH synthesis or catalase, inhibitors of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3 kinases), aging of the culture, or combination of these insults. PK-KO glia was less susceptible than WT to Fe2+ plus H2O2 and less responsive to protection by deferoxamine. Old WT glia increased the expression of heat shock protein 70, but PK-KO did not. Glia conditioned medium (GCM) from PK-KO was less neuroprotective and had lower levels of GSH than WT. GCM from WT increased the levels of dopamine markers in midbrain neuronal cultures transferred to EF12 more efficiently than GCM from PK-KO, and the difference was corrected by supplementation with GSH. PK-KO-GCM was a less powerful suppressor of apoptosis and microglia in neuronal cultures. Our data prove that abnormal glial function is critical in parkin mutations, and its role increases with aging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199761      PMCID: PMC6670347          DOI: 10.1523/JNEUROSCI.4609-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.

Authors:  Nicolas Giguère; Consiglia Pacelli; Caroline Saumure; Marie-Josée Bourque; Diana Matheoud; Daniel Levesque; Ruth S Slack; David S Park; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

2.  Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models.

Authors:  Preeti J Khandelwal; Alexander M Herman; Hyang-Sook Hoe; G William Rebeck; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2011-03-04       Impact factor: 6.150

3.  Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Authors:  Junchao Tong; Lee-Cyn Ang; Belinda Williams; Yoshiaki Furukawa; Paul Fitzmaurice; Mark Guttman; Isabelle Boileau; Oleh Hornykiewicz; Stephen J Kish
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

4.  Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Authors:  Gregory J Michael; Sharmin Esmailzadeh; Linda B Moran; Lynne Christian; Ronald K B Pearce; Manuel B Graeber
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 5.  Astrocytes conspire with neurons during progression of neurological disease.

Authors:  James C McGann; Daniel T Lioy; Gail Mandel
Journal:  Curr Opin Neurobiol       Date:  2012-04-03       Impact factor: 6.627

Review 6.  Deep brain stimulation: are astrocytes a key driver behind the scene?

Authors:  Albert J Fenoy; Laurent Goetz; Stéphan Chabardès; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2014-01-24       Impact factor: 5.243

Review 7.  Astrocytes and therapeutics for Parkinson's disease.

Authors:  Phillip M Rappold; Kim Tieu
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 8.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

9.  The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease.

Authors:  Agnieszka Ciesielska; I Joniec; I Kurkowska-Jastrzebska; A Cudna; A Przybyłkowski; A Członkowska; A Członkowski
Journal:  Inflamm Res       Date:  2009-11       Impact factor: 4.575

Review 10.  The multiple mechanisms of amyloid deposition: the role of parkin.

Authors:  Maria A Mena; José A Rodríguez-Navarro; Justo García de Yébenes
Journal:  Prion       Date:  2009-01-09       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.